Gort, Eelke

Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

Desai, J., Alonso, G., Kim, S. H., Cervantes, A., Karasic, T., Medina, L., Shacham-Shmueli, E., Cosman, R., Falcon, A., Gort, E., et al. (2024) · Nature Medicine

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 144

524P A Phase I, Open-Label, Dose-Escalation Trial of BI 1701963 in Patients (Pts) with KRAS Mutated Solid Tumours: A Snapshot Analysis

Johnson, M. L., Gort, E., Pant, S., Lolkema, M. P., Sebastian, M., Scheffler, M., Hwang, J., Dünzinger, U., Riemann, K., Kitzing, T., et al. (2021) · Annals of Oncology

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 34

Abstract CT029: Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutation

Desai, J., Han, S.-W., Lee, J.-S., Shacham-Shmueli, E., Massarelli, E., Cervantes, A., Garralda, E., Falcon, A., Miller, W. H., Gort, E., et al. (2023) · Cancer Research

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 10